This page reviews peer-reviewed research on pulsed electromagnetic field exposure in studies with mood-related endpoints. It documents study design, PEMF parameters, and reported findings. Nothing on this page is medical advice, and PEMF is not a treatment for any mental-health condition. Consult a qualified physician for any medical concern.
What is actually FDA-cleared for depression
The first distinction is regulatory. In 2008, FDA granted a De Novo classification and marketing authorization for the NeuroStar TMS System for a defined major depressive disorder population, recorded as DEN070003 and associated with K061053. That is not an ordinary 510(k) substantial-equivalence decision, and it is not an FDA approval. It is, however, the beginning of FDA-authorized prescription rTMS systems for a specified depression indication. Later FDA 510(k) substantial-equivalence decisions include the BrainsWay Deep TMS System, K122288, and the MagVita TMS Therapy System, K150641. The MagVita theta-burst system was also cleared under K173620. (FDA DEN070003; K122288; K150641; K173620.)
These records apply to the named systems, their cleared labeling, and prescription use. They do not authorize a general-wellness mat, a local PEMF applicator, or a transcranial pulsed electromagnetic field headband. The regulation for the rTMS device type, 21 CFR 882.5805, is a classification rule, not a transferable permission for every product that emits magnetic fields. Field strength does not transfer an indication from one device to another. (FDA DEN070003; K122288; K150641; K173620.)
rTMS means repetitive transcranial magnetic stimulation. A trained clinical team positions a coil at a defined scalp target and uses a prescribed protocol. The technology, visit schedule, target, safety procedures, and eligibility criteria are all part of the particular system and clinical setting.
The original live page cited a 1997 review by Kirkcaldie, Pridmore, and Pascual-Leone. It is historical TMS literature, not evidence about T-PEMF or a wellness mat, and it predates the named FDA records discussed here. Citation: Kirkcaldie MTK, Pridmore SA, Pascual-Leone A. Transcranial magnetic stimulation as therapy for depression and other disorders. Australian & New Zealand Journal of Psychiatry. 1997;31(2):264-272. PMID: 9140635. DOI: 10.3109/00048679709073830.
The three technologies people confuse
| rTMS | T-PEMF | Wellness PEMF mat | |
|---|---|---|---|
| FDA status for depression | Named prescription systems have FDA authorization or 510(k) clearance for specific MDD labeling: DEN070003/K061053, K122288, K150641, and K173620 | Not FDA-cleared; device-specific research is under investigation | No depression indication; ElectroMeds describes its devices as general wellness |
| Induced electric field | About 90 V/m in the older Re5 paper’s literature context, not a universal cleared-system specification (DOI: 10.1192/j.eurpsy.2020.3) | Older Re5 report: near 0.0004 V/m; not a generic headband value (PMID: 32093804) | No validated intracranial brain-stimulation characterization identified in reviewed records |
| Peak magnetic field | About 1.5 T at the coil is a generic 1-2 T TMS physical context, not a named MDD-system specification (DOI: 10.3389/fnhum.2021.639640) | MoodHeadBand protocol: 1.59 mT maximum at the device, a device-specific external measure (PMID: 41120157) | No verified, comparable brain-stimulation field specification used here |
| Delivery | Focal scalp coil over a planned brain target | Older Re5 seven-coil helmet; current MoodHeadBand protocol uses 20 coils | Whole-body mat or local applicator, depending on product |
| Setting | Prescription clinical setting and supervision for the named MDD systems | Older cohort included home self-administration after instruction; current sham-controlled protocol is home-based | Home general wellness |
| Evidence relevant to depression | FDA-authorized systems and a broader rTMS clinical evidence base | Small, device-specific studies with mixed controlled results; no results posted for the current MoodHeadBand protocol | No identified depression trials of general-wellness mats |
The often repeated roughly 225,000-fold contrast is simple arithmetic from one older paper: 90 V/m divided by 0.0004 V/m. It compares the rTMS reference and the Re5 T-PEMF value reported in that paper, not every rTMS system with every pulsed-field device. The numbers may have different measurement contexts, waveforms, pulse durations, coil layouts, and target anatomy. This is a physical contrast, not a measure of clinical dose, safety, outcome, or regulatory equivalence. (PMID: 32093804; DOI: 10.1038/s41598-020-68687-8.)
The labels matter because the devices do different things in different settings. A peak magnetic field at a coil is not the same quantity as an electric field estimated in tissue. Even within rTMS, coil position, head anatomy, conductivity, orientation, and pulse settings affect the field distribution. A mat’s surface output, if stated by a manufacturer, would not by itself establish a field at a brain target. (DOI: 10.1038/s41598-020-68687-8.)
T-PEMF: the research that is actually about pulsed fields
The most directly relevant recent Danish report was an eight-week, multicentre augmentation cohort of 58 adults with treatment-resistant depression. It used the older Re5 system, a helmet with seven coils, not the later MoodHeadBand. Participants used it for 30 minutes daily while their other care continued. The published cohort included 20 men and 38 women; 52 of 58 completed, and 19 had not responded to ECT in the current episode. (Larsen et al., 2020; PMID: 32093804; DOI: 10.1192/j.eurpsy.2020.3; NCT03556735.)
Its symptom results are within-cohort observations. Mean HAM-D17 was 20.6 (SD 4.0) at baseline and 12.6 (SD 7.1) at endpoint. Using last observation carried forward, 39.7% met the study response definition and 24.1% met its remission definition overall. The paper also reported episode-duration groups: response was 48.5% for nonchronic episodes and 28.0% for chronic episodes; remission was 30.3% and 16.0%, respectively. Those are exact LOCF, duration-stratified figures, not separate controlled comparisons. (PMID: 32093804; DOI: 10.1192/j.eurpsy.2020.3.)
The design limitation is decisive: this was a single-arm study with no sham group and no randomization. Observed changes cannot be separated from placebo effects, the natural course of symptoms, concurrent medication, clinical contact, psychotherapy, or other care. The authors themselves identified spontaneous remission, expectation, treatment as usual, and confounding as unresolved. The study also used LOCF for missing data, while participants had variable medication regimens. It therefore cannot show a T-PEMF-specific effect. (PMID: 32093804; NCT03556735.)
Earlier Danish work should not be erased, but it also needs careful labels. A five-week, double-blind, sham-controlled study by Martiny, Lunde, and Bech was registered with 50 actual participants and reported a HAM-D17 standardized effect size of 0.62, with a 95% confidence interval from 0.21 to 1.02. It was small and short. (PMID: 20385376; DOI: 10.1016/j.biopsych.2010.02.017; NCT00287703.) A 2014 study compared once-daily with twice-daily active schedules, so its eight-week remission percentages do not answer an active-versus-inactive question. (PMID: 25241755; DOI: 10.1017/neu.2014.5.)
The literature is not all in one direction. A separate 2021 double-blind, sham-controlled study in treatment-resistant depression found no clinical active-sham difference. A 2025 imaging analysis from that research reported brain-activation differences without a clinical antidepressant effect. Different devices and exposures prevent a simple verdict across all work, but these findings reinforce the need for completed, device-specific sham-controlled data. (PMID: 34333176; DOI: 10.1016/j.jad.2021.07.087; PMID: 38580858; DOI: 10.1007/s00406-024-01797-w.)
The trial that will answer this question is still running
NCT06005103 is the registered MoodHeadBand active-versus-sham protocol. Its published protocol describes a double-blind, randomized, parallel study in which participants use an active or identical inactive headband for 30 minutes daily for eight weeks while treatment as usual continues. It is the sort of design needed to separate a device-specific signal from expectation and other concurrent influences. A protocol is not an outcome study. (PMID: 41120157; DOI: 10.1136/bmjopen-2025-104474; NCT06005103.)
The dated registry record requires precision. It lists RECRUITING, last status verified in August 2025, and estimated primary and study completion on 2026-08-30. Its hasResults field was false when checked, and no completed results paper was located in the reviewed sources. The section heading reflects the brief, but the safely dated statement is that the registry had a recruiting label and no posted results at the time checked; it is not a fresh confirmation of present operations. (NCT06005103.)
The protocol paper describes 96 participants, or 48 per arm. The registry later estimates 117 because data from the first 21 participants could not be used to assess the antidepressant question after technical difficulties; it says those difficulties were addressed. That difference matters. The MoodHeadBand also differs from Re5: its protocol describes 20 coils, each with 187 turns, and reports 1.59 mT plus 0.050 V/m at one centimetre from the coils. Those device-specific measurements should not be substituted for the older Re5 figures. (PMID: 41120157; NCT06005103.)
Other magnetic-field research on mood
A 2019 low-field magnetic stimulation, or LFMS, pilot is related but distinct from the Danish T-PEMF work. In 30 adults with treatment-resistant major depressive disorder, 15 received active stimulation and 15 sham stimulation through a specialized head coil using an MRI-spectroscopy waveform. After the third of three 20-minute sessions, two immediate mood measures differed between groups, while other outcomes did not. The study did not assess durability, and its reported field was an electric field of no more than 1 V/m at 1 kHz rather than a comparable peak magnetic-field figure. (PMID: 30784726; DOI: 10.1016/j.jad.2019.02.039; NCT01944644.)
A 2025 neck-worn PEMF volunteer study is not depression research. It used one named wearable with sham, 6 Hz, 16 Hz, or 32 Hz programs and a 2.5 mT peak specification. Its outcomes were self-rated sleep and anxiety, not a depression diagnosis or depression scale, and it did not directly demonstrate vagus-nerve activation. Initial enrollment was 485 volunteers, but reported response counts were lower and inconsistent across time points. It should not be used to make a depression inference. (PMID: 39972609; DOI: 10.1080/15368378.2025.2462649.)
Multiple-sclerosis evidence is adjacent evidence, not depression-treatment evidence. A 2025 review covered eight heterogeneous MS trials and found that the three studies measuring depressive symptoms showed no significant active-control difference. A separate 2025 meta-analysis likewise reported no significant effect on depressive symptoms. These were MS populations, not major depressive disorder cohorts, and depression was not the central question. (DOI: 10.5812/ans-147080; PMID: 40540924; DOI: 10.1016/j.msard.2025.106549.) No identified trials evaluate general-wellness PEMF mats for depression.
How strong is this evidence?
The evidence is not one body of interchangeable research. rTMS has named FDA-authorized systems and an established clinical research literature. T-PEMF studies are smaller, device-specific, and methodologically mixed. The 2020 cohort is informative about what happened in that group, but not about the portion of change attributable to its seven-coil device. The 2010 sham-controlled trial is an important early signal, while the later controlled negative study is an important counterweight. (PMID: 32093804; PMID: 20385376; PMID: 34333176.)
A strong test needs an inactive comparator, blinding, adequate sample size, clear device specifications, prespecified outcomes, complete reporting, and follow-up. NCT06005103 is designed around several of those features, but there are no posted clinical results to evaluate. The technical issue is equally important: Re5, MoodHeadBand, the Dutch study device, LFMS equipment, neck wearables, and mats cannot be treated as one exposure simply because each involves a magnetic field. (NCT06005103; PMID: 41120157; PMID: 30784726.)
The 2020 cohort also should not be read as a comparison with rTMS, ECT, medication, psychotherapy, or no additional intervention. It made none of those comparisons. Its numerical changes describe one group receiving an added device while continuing varied care. The 2010 study is a small early sham-controlled finding, but its sample size and five-week duration leave substantial uncertainty. The 2021 controlled result makes the appropriate overall description mixed and incomplete, rather than either dismissive or promotional. (PMID: 32093804; PMID: 20385376; PMID: 34333176.)
Research labels can be misleading when they omit the outcome timeframe. The LFMS pilot assessed immediate effects after a few sessions. The neck wearable study collected self-reported sleep and anxiety ratings in volunteers. The MS reviews address a different disease population and heterogeneous interventions. None supplies a reliable shortcut from magnetic field to a conclusion about a wellness mat and depression. The useful question is which exact intervention was studied, in whom, against what comparison, for how long, and with what outcome. (PMID: 30784726; PMID: 39972609; DOI: 10.5812/ans-147080.)
Numbers can clarify a physical distinction without settling a clinical question. The 225,000 calculation says nothing by itself about benefit, harm, who may be eligible, or which device meets a regulatory standard. It also does not bridge a head-worn research apparatus and a body mat. The absence of identified mat trials for depression is a gap in evidence, not a reason to import results from a different device or population.
What this means if you are considering a PEMF device
ElectroMeds systems are general-wellness devices, not depression treatments, and they are not a substitute for psychiatric care. The rTMS records discussed above do not extend to them. If depression is part of your situation, discuss symptoms, options, and any interest in a device with a qualified clinician who knows your history. Stopping antidepressant medication without medical supervision is dangerous, and nothing on this page is a reason to do it.
Ask whether a statement names the exact device, population, comparison group, outcome, and follow-up period. A claim that shifts from a head-worn study to a mat, or from a short-term questionnaire to depression, leaves the evidence behind. Anyone experiencing thoughts of self-harm should contact a doctor or a crisis line immediately.
Practical questions can be taken to a clinician or a research team: whether a study has an inactive control, whether usual care continues, whether adverse events and withdrawals are reported, and whether the device in question is the device in the paper. Those questions do not require a person to decide that every magnetic-field technology is the same. They help keep a regulation number, a physical specification, a research protocol, and a consumer product description in their proper categories.
The evidence review here is deliberately narrower than a product discussion. It does not establish an indication for a mat, confirm a manufacturer output figure, or rank devices by field strength. A cautious decision starts with the difference between an FDA-authorized prescription rTMS system, an investigational T-PEMF headband, and a general-wellness PEMF product.
Common questions
Is PEMF FDA approved for depression?
No general statement that PEMF is FDA approved for depression is accurate. Specific prescription rTMS systems have FDA authorization or 510(k) clearance for defined major depressive disorder labeling, while the T-PEMF headband studies described here are not FDA-cleared. General-wellness PEMF mats have no depression indication. (FDA DEN070003; K122288; K150641.)
Is TMS the same as PEMF?
No. rTMS is a prescription brain-stimulation technology with named FDA records for specified uses. T-PEMF is a separate low-field, head-worn research category, and a wellness PEMF mat is another category again. Similar words about magnetic fields do not make them equivalent. (PMID: 32093804; PMID: 41120157.)
What is T-PEMF?
T-PEMF means transcranial pulsed electromagnetic fields. In the depression studies discussed here, it refers to head-worn coil arrays such as the older seven-coil Re5 helmet and the 20-coil MoodHeadBand protocol. It is under investigation, not FDA-cleared for depression. (PMID: 32093804; PMID: 41120157; NCT06005103.)
Can a PEMF mat help depression?
No identified trials evaluate general-wellness PEMF mats for depression. Research on rTMS, T-PEMF headbands, LFMS, neck wearables, or MS populations cannot be assumed to apply to a mat. A general-wellness product does not gain a depression indication from research on a different technology. (PMID: 30784726; DOI: 10.5812/ans-147080.)
Does insurance cover TMS for depression?
Coverage depends on the insurer, plan, diagnosis, prior-authorization rules, the named system, and local clinical documentation requirements. FDA authorization does not guarantee coverage, and an insurance decision is separate from the evidence questions on this page. A prescribing clinic and insurer can explain the current requirements for an individual plan. (FDA DEN070003; K122288.)
This page summarizes published research for reference. It is not medical advice, and nothing here is a claim that any PEMF device treats, cures, or prevents any condition. PEMF is not appropriate for everyone — review PEMF contraindications and talk with your own physician before beginning any new therapy, particularly if you have an implanted electronic device, are pregnant, or are being treated for a serious medical condition.